Despite the availability of an effective measles virus(MeV)vaccine and efforts to increase vaccine coverage by the WHO,UNICEF,and their partners,MeV has not been eradicated,and the estimated global measles death rose ...Despite the availability of an effective measles virus(MeV)vaccine and efforts to increase vaccine coverage by the WHO,UNICEF,and their partners,MeV has not been eradicated,and the estimated global measles death rose from 89,780 in 2016 to 207,500 in 2019.1 Because there is an effective measles vaccine,antiviral development for measles has not been prioritized,but recent outbreaks have highlighted the need for drugs to prevent transmission in unvaccinated populations and to protect and treat immunocompromised individuals.We identified several neutralizing mouse monoclonal antibodies(mAbs)that target the MeV fusion(F)protein in its prefusion state2 and inhibit fusion and viral infection.We engineered a single-chain variable fragment(scFv)from the most potent anti-MeV F mAb.The scFv retains the ability to inhibit fusion and prevents infection in vitro,and intranasal administration of the scFv antibody construct prevents infection in vivo.展开更多
基金supported by grants from the NIH:All21349,NS091263,and NS105699,Al 146980 to M.P.,from the French ANR NITRODEP(ANR-13-PDOC-OO10-01)to C.M.and from the Region Auvergne Rhone Alpes and LABEX ECOFECT(ANR-11-LABX-0048)of Lyon University within the program"Investissements d'Avenir"(ANR-11-IDEX-0007),operated by the French National Research Agency(ANR)to B.H.The Sharon Golub Fund at Columbia University Irving Medical Center(CUIMC).
文摘Despite the availability of an effective measles virus(MeV)vaccine and efforts to increase vaccine coverage by the WHO,UNICEF,and their partners,MeV has not been eradicated,and the estimated global measles death rose from 89,780 in 2016 to 207,500 in 2019.1 Because there is an effective measles vaccine,antiviral development for measles has not been prioritized,but recent outbreaks have highlighted the need for drugs to prevent transmission in unvaccinated populations and to protect and treat immunocompromised individuals.We identified several neutralizing mouse monoclonal antibodies(mAbs)that target the MeV fusion(F)protein in its prefusion state2 and inhibit fusion and viral infection.We engineered a single-chain variable fragment(scFv)from the most potent anti-MeV F mAb.The scFv retains the ability to inhibit fusion and prevents infection in vitro,and intranasal administration of the scFv antibody construct prevents infection in vivo.
